Scholarlink

<p>Colorectal cancer (CRC) poses significant challenges due to its high incidence and mortality. Addressing limitations like poor bioavailability and off-target effects of traditional chemotherapy, we engineered PDMS-CP1@1@Capecitabine nanoparticles. This novel formulation incorporates a gadolinium-based coordination polymer synthesized via a hydrothermal reaction with a thiourea Schiff-base ligand and embedded in a polydimethylsiloxane (PDMS) matrix, enhanced by the bioactive compound 1 from actinomycetes. Structural characterization demonstrated a crystalline nature with distinct XRD peaks at 21.4° and 25.6°, alongside remarkable fluorescence with peak emission at 444&#xa0;nm and superior Fe<sup>3+</sup> selectivity, showing 90% quenching efficiency against Fe<sup>3+</sup> compared to other ions. These nanoparticles reduced CRC cell viability by up to 55% at 20&#xa0;µg/mL, modulating USP22 and HSP90 expression, validated by molecular docking confirming hydrogen bonding interactions. PDMS-CP1@1@Capecitabine emerges as a potent targeted therapy for CRC, enhancing drug delivery and offering a novel approach for iron monitoring, pivotal for personalized treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual-Functional Silicon-Based Nanofluorescent Platform for Iron Detection and Capecitabine Delivery in Colorectal Cancer Treatment

  • 期刊论文

  • 发表日期：

    2025年3月21日

查看全文
  • Xuewei Fang,
  • Tielong Wang,
  • Yinjie Zhang,
  • Jingli Song

摘要

Colorectal cancer (CRC) poses significant challenges due to its high incidence and mortality. Addressing limitations like poor bioavailability and off-target effects of traditional chemotherapy, we engineered PDMS-CP1@1@Capecitabine nanoparticles. This novel formulation incorporates a gadolinium-based coordination polymer synthesized via a hydrothermal reaction with a thiourea Schiff-base ligand and embedded in a polydimethylsiloxane (PDMS) matrix, enhanced by the bioactive compound 1 from actinomycetes. Structural characterization demonstrated a crystalline nature with distinct XRD peaks at 21.4° and 25.6°, alongside remarkable fluorescence with peak emission at 444 nm and superior Fe3+ selectivity, showing 90% quenching efficiency against Fe3+ compared to other ions. These nanoparticles reduced CRC cell viability by up to 55% at 20 µg/mL, modulating USP22 and HSP90 expression, validated by molecular docking confirming hydrogen bonding interactions. PDMS-CP1@1@Capecitabine emerges as a potent targeted therapy for CRC, enhancing drug delivery and offering a novel approach for iron monitoring, pivotal for personalized treatment strategies.